JPMorgan Chase & Co. Issues Positive Forecast for Cardinal Health (NYSE:CAH) Stock Price

Cardinal Health (NYSE:CAH) had its price target hoisted by JPMorgan Chase & Co. from $215.00 to $260.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 12.12% from the stock’s current price.

CAH has been the topic of several other research reports. William Blair initiated coverage on shares of Cardinal Health in a research note on Tuesday, April 28th. They set an “outperform” rating on the stock. Barclays raised their price objective on Cardinal Health from $258.00 to $275.00 and gave the stock an “overweight” rating in a report on Thursday. Morgan Stanley upped their target price on Cardinal Health from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Wednesday. Wells Fargo & Company raised their price target on Cardinal Health from $245.00 to $277.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Leerink Partners set a $292.00 price objective on shares of Cardinal Health in a research note on Tuesday. Fifteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $265.60.

Cardinal Health Trading Down 1.0%

Shares of CAH stock traded down $2.27 during trading hours on Thursday, hitting $231.89. The company’s stock had a trading volume of 489,648 shares, compared to its average volume of 2,030,364. The business has a fifty day moving average of $229.13 and a 200-day moving average of $216.86. Cardinal Health has a twelve month low of $145.87 and a twelve month high of $258.30. The stock has a market cap of $54.31 billion, a price-to-earnings ratio of 32.07, a P/E/G ratio of 1.13 and a beta of 0.49.

Cardinal Health (NYSE:CAH) last released its quarterly earnings results on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.42 by $0.49. Cardinal Health had a negative return on equity of 98.74% and a net margin of 0.67%.The company had revenue of $63.67 billion during the quarter, compared to analysts’ expectations of $65.15 billion. During the same period in the previous year, the firm posted $2.08 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities analysts expect that Cardinal Health will post 12.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Cardinal Health

Several hedge funds and other institutional investors have recently bought and sold shares of CAH. Kornitzer Capital Management Inc. KS grew its holdings in Cardinal Health by 100.8% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 18,164 shares of the company’s stock worth $3,733,000 after acquiring an additional 9,120 shares in the last quarter. Abacus FCF Advisors LLC acquired a new stake in shares of Cardinal Health in the 4th quarter valued at about $7,182,000. Byrne Financial Freedom LLC bought a new position in shares of Cardinal Health during the fourth quarter worth about $1,574,000. Belleair Asset Management LLC bought a new position in shares of Cardinal Health during the fourth quarter worth about $1,100,000. Finally, Axecap Investments LLC acquired a new position in Cardinal Health in the fourth quarter worth about $2,371,000. 87.17% of the stock is owned by institutional investors and hedge funds.

Cardinal Health News Summary

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Earnings and outlook: Fiscal fourth-quarter adjusted EPS of $2.91 exceeded estimates by $0.49, while management projected 13%–15% fiscal 2027 EPS growth. Strength in pharmaceutical distribution, specialty products, At-Home Solutions and medical technology supported the outlook. CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up
• Positive Sentiment: Analyst target increases: Citigroup raised its target to $280 with a Buy rating, Wells Fargo lifted its target to $277 with an Overweight rating, and Baird increased its target to $274 with an Outperform rating. The revisions reflect confidence in earnings growth and execution. Cardinal Health Analysts Increase Their Forecasts Following Q4 Results
• Positive Sentiment: Capital returns and strategic momentum: Cardinal Health expanded its share-repurchase authorization, while its 29-year dividend-growth streak and nearly doubled medical-technology profit provide additional support for shareholders. Cardinal Health nearly doubles medtech profits, fueling Q4 earnings beat
• Neutral Sentiment: Dividend maintained: The company declared a quarterly dividend of $0.5158 per share, payable October 15, equivalent to an annualized yield of approximately 0.9%. The payout reinforces income and capital-return appeal but is modest relative to the share price.
• Negative Sentiment: Revenue miss and valuation risk: Quarterly revenue of $63.67 billion fell short of the $65.15 billion consensus estimate. After the stock’s sharp run to an all-time high, investors may be questioning whether strong earnings expectations and the company’s cash-generation story are already reflected in the valuation. Cardinal Health misses Q2 CY2026 sales expectations

About Cardinal Health

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.